Sandra Milligan

Responsable de la Recherche et Développement

Organon & Co.Gossamer Bio, Inc.Aspira Women's Health Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 1 buy · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€66k

▼ Sales (0 ops.)

—

Latest filing published 20 Aug 2025 for Gossamer Bio, Inc., €43k.

Filing timeline

BuySale

Sandra Milligan

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+44.7%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Sandra Milligan: trading record in brief

This profile gathers the share dealings of Sandra Milligan across 3 companies, led by Organon & Co., Aspira Women's Health Inc. and Gossamer Bio, Inc. We count 21 filings; the first trade dates from 28 February 2022 and the latest from 19 August 2025.

Every open-market trade on record is a purchase: 2 purchases worth €66k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 9 share grants and 10 option exercises. Since January 2025: 1 purchase and no sales on the market.

The latest filing, published on 20 August 2025, reports an open-market purchase of €43k in Gossamer Bio, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.